Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin's lymphoma.
An association between autoimmunity and hematological malignancies has been reported including the detection of antinuclear autoantibodies (ANAs) in patients suffering from non-Hodgkin's lymphoma (NHL), with a high prevalence of ANAs directed to components of the mitotic apparatus or the mitosis-associated proteins. Previous studies have demonstrated that one of the targets of such ANAs could be the CENP-F protein, especially in some carcinomas. The prevalence and specificity of anti-CENP-F autoantibodies (aAbs) thus were analyzed in 347 patients with different histological subgroups of NHL before any treatment of NHL, along with 150 controls. The detection of these aAbs was performed using two techniques: a radioimmunological assay (RIA) and an indirect immunofluorescence technique (IIF). Twenty-five (7.2%) NHL patients and 2 (1.3%) control patients displayed anti-CENP-F aAbs using RIA. This difference between the two groups was found to be significant (P < 0.01), with a higher prevalence of aAbs in the follicular (13%) and in the marginal zone B and MALT (10.2%) lymphoma subgroups. By IIF, 10 (2.9%) patients with NHL displayed aAbs with a CENP-F or CENP-F-like pattern, whereas none of the control group did. In conclusion, these data demonstrate that a significant incidence of anti-CENP-F aAbs is observed, before any treatment, in some histological subgroups of NHL patients. In addition to the usefulness of anti-CENP-F aAbs as a marker for some NHL subgroups, prospective studies may be important to evaluate the predictive value of anti-CENP-F aAbs for the development of carcinomas.
Bencimon
Celine
C
Laboratoire d'Auto-Immunité, Centre Hospitalier Lyon-Sud (Hospices Civils de Lyon), Chemin du Grand Revoyet, 69495 Pierre-Bénite cedex, France.
Salles
Gilles
G
Moreira
Annick
A
Guyomard
Stephanie
S
Coiffier
Bertrand
B
Bienvenu
Jacques
J
Fabien
Nicole
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000974:Antibodies, Antinuclear / Q000097:blood*; D001324:Autoantigens / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D002868:Chromosomal Proteins, Non-Histone / Q000276:immunology*; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology* / Q000276:immunology*; D008297:Male; D008840:Microfilament Proteins; D008875:Middle Aged; D011233:Precipitin Tests; D015995:Prevalence; D011863:Radioimmunoassay; D012680:Sensitivity and Specificity
D000974:Antibodies, Antinuclear; D001324:Autoantigens; D015415:Biomarkers; D002868:Chromosomal Proteins, Non-Histone; D008840:Microfilament Proteins; C094772:centromere protein F